Brief: Oncolytics Biotech's Pelareorep Selected For Inclusion In Precision PromiseSM Pivotal Phase 3 Platform Trial
22/06/2023 12:13
June 22 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH'S® PELAREOREP SELECTED FOR INCLUSION IN
PRECISION PROMISESM PIVOTAL PHASE 3 PLATFORM TRIAL
Source text for Eikon: ID:nCNW10Pmma
Further company coverage: ONC.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer